Normal Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Normal
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Normal News
Scientists Discover Brain Cancer Begins in “Normal” Cells Long Before Tumors Appear
New research reveals that certain brain tumors may originate silently within normal brain cells long before a tumor forms. IDH-mutant glioma is a malignant brain cancer linked to changes in a single ...
Delhi’s Toxic Air Made Me Try This Tiny Wearable Air Purifier And Here Is My Take
The product I tested is called the Atovio Pebble, a tiny personal air purifier that you wear around your neck like a pendant. Available at Rs 2,999 on Amazon, the device is made in India and the ...
Puberphonia: what happens when the voice does not change after puberty
Discover puberphonia, a voice condition where pitch remains high post-puberty, and explore its causes, assessment, and treatment options.
Structure-based RNA could lead to treatment for neuromuscular disorders
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...